Snellgrove Darren

Darren Snellgrove holds the position of Senior Vice President at Halozyme Therapeutics, Inc., a company focused on developing innovative therapies for cancer and other diseases. His recent disclosures, all reported on July 2, 2026, reveal significant insider activity, including two public filings related exclusively to Halozyme Therapeutics (HALO). The disclosed transactions amount to approximately $9.8 million, with the largest move being a grant or exercise valued at $9,813,538.32.